Atorvastatin reduces vascular endothelial growth factor (VEGF) expression in human non-small cell lung carcinomas (NSCLCs) via inhibition of reactive oxygen species (ROS) production

作者：Chen, Jie; Liu, Bing; Yuan, Jiayi; Yang, Jie; Zhang, Jingjie; An, Yu; Tie, Lu; Pan, Yan; Li, Xuejun^*

来源：Molecular Oncology, 2012, 6(1): 62-72.

DOI：10.1016/j.molonc.2011.11.003

• Non-small cell lung cancers
• NSCLCS
• Vascular endothelial growth factor
• VEGF
• Reactive oxygen species
• ROS
• NADPH oxidase
• Atorvastatin

The high metastatic potential of non-small cell lung cancers (NSCLCs) is closely correlated with the elevated expression of vascular endothelial growth factor (VEGF) and resultant tumor angiogenesis. However, no effective strategies against VEGF expression have been available in NSCLCs therapy. This study demonstrated that elevated reactive oxygen species (ROS) levels derived from both mitochondria and NADPH oxidase were required for VEGF expression in NSCLC cells. Atorvastatin administration could significantly inhibit VEGF expression both in vitro and in vivo via inhibition of ROS production. Atorvastatin inhibited ROS generation partly through suppression of Rac1/NADPH oxidase activity. Specifically, atorvastatin could upregulate the activity of glutathione peroxidase (GPx) and catalase, which are responsible for elimination of hydrogen peroxide (H2O2) in the mitochondria and peroxisomes, respectively. Thus, inhibition of ROS production by concomitant suppression of Rac1/NADPH oxidase activity and upregulation of the activity of GPx and catalase contributes critically to atorvastatin-reduced VEGF expression in NSCLCs. Atorvastatin may be a potential alternative against VEGF expression and angiogenesis in NSCLCs therapy.

• 出版日期2012-2
• 单位广西医科大学; 广东药科大学; 北京大学